AbCellera Biologics (ABCL) Assets (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Assets data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Assets fell 2.76% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 2.76% YoY) and the FY2025 annual result came in at $1.4 billion, changed 0.26% from the prior year.
• Assets fell to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Assets ranged from a high of $1.6 billion in Q2 2022 to a low of $1.3 billion in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets surged 41.09% — and 2024, when it decreased 8.57%.
• Tracing ABCL's Assets over 5 years: stood at $1.5 billion in 2022, then fell by 3.43% to $1.5 billion in 2023, then declined by 8.57% to $1.4 billion in 2024, then decreased by 0.26% to $1.4 billion in 2025, then slipped by 3.67% to $1.3 billion in 2026.
• The last three Assets figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.